CXCR4 and neoplasm: Lastly, CXCR4, a marker of NB aggressiveness and metastasis, and a target for p53 transactivation, was consistently downregulated after PRIMA-1MET treatment, suggesting a potential benefit of PRIMA-1MET in inhibiting tumor spread (Fig. 3B).